Oruka Therapeutics, Inc.
ORKAHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeOruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I). The company carries a $6.13B market cap, placing it firmly in the mid-cap category. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Market Cap
$6.13B
Beta
-0.21
P/E (TTM)
—
P/E (Fwd)
-32.32
EPS (TTM)
$-2.04
EPS (Fwd)
$-2.86
ROE
-18.2%
ROA
-13.0%
Cash
$873.6M
Total Debt
$2.5M
Free CF
-$65.0M
52W Change
485.5%
Annual Financials
Cash vs Debt
Where ORKA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ORKA finished 37.56% above its 150-day moving average ($66.61) and 59.22% above its 200-day moving average ($57.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORKA overbought or oversold?
At the September 3, 2026 close, ORKA's RSI(14) was 26.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $873.6M in cash and $2.5M in debt, ORKA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$65.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.21 suggests ORKA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ORKA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ORKA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.